EU Allows Pharma To Temporarily Prioritize Reporting For COVID-19 Adverse Events
Prioritization Allowed Until The Pandemic Is Resolved
Executive Summary
Drug companies unable to continue with standard reporting of suspected adverse reactions to the EU pharmacovigilance database can temporarily prioritize their reporting activities to focus on COVID-19 related safety events.
You may also be interested in...
EMA Proposes Extending Remote QP Batch Certification Post-Pandemic
Stakeholders given one month to weigh in on proposal to allow relaxations introduced in response to COVID-19-related travel restrictions to continue on a routine basis.
COVID-19 Pandemic Pushes EU To Extend GMP/GDP Certificate Validity
As the COVID-19 pandemic continues to pose difficulties in conducting on-site inspections to check compliance with good manufacturing and distribution requirements, regulators in the EU have extended the validity of existing certificates and time-limited authorizations till the end of next year.
World’s Pharmaceutical Inspectorates Prepare For Post-Pandemic Remote Site Assessments
US, EU, global authorities share experiences, insights, advice for industry on remote alternatives even after inspectors can resume travels.